echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > A brief application for a new drug for Lochatan potassium tablets filed by Haizheng Pharmaceuticals to the U.S. FDA has been approved

    A brief application for a new drug for Lochatan potassium tablets filed by Haizheng Pharmaceuticals to the U.S. FDA has been approved

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    recently, Haizheng Pharmaceuticals announced that the
    holding company(http://Haizheng Pharmaceutical (Hangzhou) Co., Ltd("Haizheng Hangzhou Company") received a notice from the U.SFoodMedicines(http://Regulatory Authority (hereinafter referred to as the "U.SFDA(http://" notice, Haizheng Hangzhou The Company'sNew Drug(http://Application for theof The Loshatan Potassium Tablets filed with the U.SFDA, which is a u.S Pharmaceutical (http:// , and the application for FDA approval means that the applicant can produce and sell the product (http:// ) in the U.S market   About Losatan potassium tablets
    Losatan potassium tablets are mainly suitable for the treatment of hypertension, type 2 diabetes kidney disease Cozaar, the original research drug, was developed by Merck, and domestic and foreign manufacturers are mainly Zhejiang Huahai Pharmaceutical Co., Ltd., China Resources Shuanghe Pharmaceutical Co., Ltd., Beijing Shuangji Pharmaceutical Co., Ltd   So far, Haizheng Pharmaceuticals has invested about 6.8 million yuan in the drug research and development project The approval of the Losatan potash tablet ANDA by the U.S FDA marks the company's eligibility to sell the product in the U.S market, which has a positive impact on the company's expansion into the U.S market
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.